Clinical trials
Phase 3 Prostatic Neoplasms trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
75 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 3 |
| 2003 | 3 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 6 |
| 2010 | 5 |
| 2011 | 5 |
| 2012 | 1 |
| 2013 | 5 |
| 2014 | 5 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 41 |
| Active, not recruiting | 18 |
| Terminated | 9 |
| Recruiting | 5 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 10 |
| Pfizer | 7 |
| Sanofi | 5 |
| Amgen | 4 |
| Bristol-Myers Squibb | 4 |
| Aragon Pharmaceuticals, Inc. | 3 |
| European Organisation for Research and Treatment of Cancer - EORTC | 3 |
| Ferring Pharmaceuticals | 3 |
| Janssen Research & Development, LLC | 3 |
| Abbott | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prostatic Neoplasms | 75 |
| Neoplasm Metastasis | 10 |
| Neoplasms | 7 |
| Bone Diseases, Metabolic | 1 |
| Breast Neoplasms | 1 |
| Bulbo-Spinal Atrophy, X-Linked | 1 |
| Carcinoma | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Carcinoma, Ovarian Epithelial | 1 |
| Cataract | 1 |
Trials
Showing 1 to 25 of 75. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.